Theorem Clinical Research added Lisa Moore, Ph.D., as associate director of scientific affairs...TiGenix appointed Jean Stéphenne as chairman and Russel Greig, Ph.D., to its board of directors...Althea Technologies promoted Rick Hancock to president and CEO, Chris Duffy to svp of operations, and E.J. Brandreth to svp of quality and regulatory.
Alliqua added James Sapirstein as CEO...Merz promoted Hyunna Coelho to vp, commercial excellence...VitaPath Genetics appointed Catherine Burzik as chair of its board of directors...Omeros named Arnold C. Hanish to its board of directors...Lightlake Therapeutics added David Kessler, M.D., as strategic advisor...Sigma-Aldrich elected Michael Marberry as director...Igenica hired Mary Haak-Frendscho, Ph.D., as CEO.
Baxter International appointed Uma Chowdhry, Ph.D., and Thomas F. Chen to its board of directors...James Kuo, M.D., is now chairman and CEO at BioSavita...C3 Jian named Richard Bastiani, Ph.D., to its board of directors...Immunovative added Bruce Harmon as CFO...EffRx Pharmaceuticals hired Lorenzo Bosisio as head of business development and marketing...Mission Therapeutics hired Michael Moore, Ph.D., as executive chairman and Fritz Frickel as nonexecutive director.
BioRestorative Therapies named Wayne A. Marasco, M.D., Ph.D., to its scientific advisory board...InVivo Therapeutics added Bill D’Agostino as senior director of manufacturing and engineering...Peter Maag is now president and CEO at XDx...Alan J. Tuchman, M.D., joined Oncolytics Biotech as CMO.
Actinium Pharmaceuticals appointed Hagop Kantarjian, M.D., to its clinical advisory board...Novasep named Patrick Glaser as president and CEO and Roger-Marc Nicoud as non-executive chairman of the board.
Linda C. Hogan is now vp, business development at Tolera Therapeutics...Audeo Oncology appointed Leigh Bonney, Susan Kelley, M.D., and David U’Prichard, Ph.D., to its board of directors...Aratana Therapeutics elected Jay Lichter, Ph.D., as chairman and appointed John Vander Vort to its board of directors.